Patients stop meds when benefit changes

December 03, 2003

BOSTON, MA - Large increases in co-payments in tiered prescription drug plans increase the likelihood that patients will choose not to pay them and to stop taking prescribed drugs, including needed medications for chronic illnesses such as heart disease and acid reflux, according to a study in the New England Journal of Medicine.

"Tiered prescription drug plans are fairly new, but they now dominate the market with roughly 57 percent of workers in a three-tiered prescription drug plan," said lead author Haiden Huskamp, Harvard Medical School assistant professor of health economics, Department of Health Care Policy. "This is one of the first studies to show how employees being treated for chronic illnesses react to changes in their drug plans."

The study followed two employers as they changed their prescription coverage plans in 2000 to incentive formulary plans. Employer A switched from a one-tier to a three-tier plan and increased co-payments across all tiers . Employer B's employees switched from a two-tier to a three-tier formulary and increased co-payments for the third tier only. The study authors also identified two comparison groups, employers that had similar plans to Employer A and B, which allowed the authors to see what would have happened if no changes had occurred.

Employer A's workers that experienced substantial co-payment increases had a marked reaction to the changes in that some enrollees stopped taking necessary medications. For example, 16 percent of patients using tier three ACE inhibitors for their blood pressure stopped taking their medications (only 6 percent stopped in the comparison group). Twenty-one percent of patients using tier three cholesterol lowering statins stopped taking their medications (only 11 percent stopped in the comparison group), and 32 percent of patients using tier three acid-relieving proton pump inhibitors stopped taking their medications (only 19 percent stopped in the comparison group).

Employer A also saw many of its enrollees facing the largest co-payment increases switch the drug they currently took to a drug in a lower-tier. Nearly 42 percent of patients taking ACE inhibitors switched their current tier three medication to a lower-tiered drug (only 4 percent switched in the comparison group); 35 percent of patients taking tier three proton pump inhibitors switched to a lower-tiered drug (only 1 percent switched in the comparison group); and 49 percent of patients taking tier three statins switched to a lower-tiered drug (17 percent switched in the comparison group).

Due to the increase in co-payments, the enrollees in Employer A's plan experienced a dramatic change in out-of-pocket expenses. Relative to patients in the comparison group, patients in Employer A's plan paid 142 percent more for ACE inhibitors, 148 percent more for proton pump inhibitors, and 118 percent more for statins.

Conversely, Employer B did not see a significant impact in compliance or spending among its members based on its modest plan design change. However, Employer B's members were more likely to switch from a non-preferred brand name medication to a less expensive brand name or generic medication. Nearly 41 percent of patients taking ACE inhibitors switched to a lower-tiered drug (15 percent switched in the comparison group); 18 percent of patients using a proton pump inhibitors switched to a lower-tiered drug (only 2 percent switched in the comparison group); and 48 percent of patients using a tier three statin switched to a lower-tiered statin (8 percent switched in the comparison group).

"This study shows that the devil is in the details when trying to predict the effects of a formulary change," said Huskamp. "Sizeable co-payment increases could have worrisome effects."

As Medicare gets ready to implement a prescription drug benefit that relies on Pharmacy Benefit Managers and formularies to control drug costs, these results may offer insights into how a Medicare drug benefit may function in the future.

The same Harvard Medical School and Medco Health Solutions team that collaborated on this study are currently conducting another study that looks at how retirees and older employees are affected by similar changes.

The study was supported by the Robert Wood Johnson Foundation's Changes in Health Care Financing and Organization (HCFO) program, the National Institute of Mental Health, and the Agency for Healthcare Research and Quality.
-end-
HARVARD MEDICAL SCHOOL
http://www.hms.harvard.edu/

Harvard Medical School has more than 5,000 full-time faculty working in eight academic departments based at the School's Boston quadrangle or in one of 47 academic departments at 18 Harvard teaching hospitals and research institutes. Those Harvard hospitals and research institutions include Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Cambridge Hospital, The CBR Institute for Biomedical Research, Children's Hospital, Dana-Farber Cancer Institute, Forsyth Institute, Harvard Pilgrim Health Care, Joslin Diabetes Center, Judge Baker Children's Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Mental Health Center, McLean Hospital, Mount Auburn Hospital, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital, VA Boston Healthcare System.

Contacts:
John Lacey
Nicole Giese
Alison Harris
617-432-0442
public_affairs@hms.harvard.edu
http://www.hms.harvard.edu/news/index.html

Harvard Medical School

Related Ace Inhibitors Articles from Brightsurf:

New class of highly effective inhibitors protects against neurodegeneration
Heidelberg University neurobiologists have uncovered how a special receptor can lead to cell death.

Research on the impact of ACE-i and ARBs for patients with COVID-19 continues to evolve
Three research studies featured in the release related to low blood pressure, or hypotension in COVID-19 patients.

Targeting SARS-CoV-2 enzyme with inhibitors
As the COVID-19 pandemic continues to spread, many researchers are studying epidemiological models to predict its propagation.

PD-1/PD-L1 inhibitors treatment in lung cancer: Brightness and challenge
Immune-checkpoint inhibitors (ICIs) have made a significant impact on the outcomes of lung cancer patients.

Designing peptide inhibitors for possible COVID-19 treatments
Scientists across the globe are rushing to find inhibitors of SARS-CoV-2, the new coronavirus behind the COVID-19 pandemic.

ACE inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
James Diaz, MD, MHA, MPH & TM, Dr PH, Professor and Head of Environmental Health Sciences at LSU Health New Orleans School of Public Health, has proposed a possible explanation for the severe lung complications being seen in some people diagnosed with COVID-19.

Examining risk of suicide and use of ACE inhibitors, ARBs
Associations between risk of suicide and medications widely used in the management of high blood pressure, chronic kidney disease, heart failure and diabetes (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers) were examined in this observational study.

Study shows both natural variation in ACE concentrations and lowering blood pressure with ACE inhibitors are associated with lower risk of type 2 diabetes
New research presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain (Sept.

IL-1 inhibitors may reduce radiation-induced vascular damage
Radiation therapy against cancer can increase the risk of cardiovascular disease much later in life, as the radiation causes chronic inflammation of the exposed blood vessels.

Lipo-protein apheresis and PCSK9-inhibitors
This review aims to present the role of lipoprotein apheresis in the management of familial hypercholesterolaemia and discuss the potential advantages and disadvantages of its combination with PCSK9 inhibitors.It is quite clear that further investigation on possible direct and/or indirect pleiotropic effects of PCSK9-I on inflammatory molecules is necessary and to be expected.

Read More: Ace Inhibitors News and Ace Inhibitors Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.